Elanco Animal Health has announced that it is now a fully independent company after Eli Lilly and Company, Elanco´s former parent company, completed the divestiture of its ownership. This completes the journey Elanco began in 2017, when Lilly first announced potential strategic alternatives for the 64-year-old animal health company.
Elanco’s independence is a result of its diversification of the business and expansion of its global footprint – from largely a US and livestock focused business to an even split between US and international sales.
“This is a historic day for everyone at Elanco,” said Jeff Simmons, Elanco president and chief executive. “It reflects our team’s hard work over the past two years, the confidence that we have the right strategy and are successfully progressing the execution against it. With this milestone behind us, we look forward to a singular focus delivering innovative solutions and services for our customers – the farmers, veterinarians and pet owners that are central to our success. We welcome our new Elanco shareholders who join us and offer our appreciation to our customers, and Lilly for the decades of support.”
“Today marks a new chapter in Elanco’s history as we start our journey as independent animal health company,” said Tina Hunt, general manager UK & Ireland. “We understand the challenges of the global protein demand. We can’t meet growing demand simply by adding animals, we must raise our livestock animal more efficiently.”
“We are well positioned to capitalise on the strong industry growth drivers and look forward to building a bright future together with our customers and our employees”, adds Tina Hunt.
